Sermorelin Co

Compounded, not FDA-approved

Sermorelin works upstream: it asks your pituitary for growth hormone instead of replacing it.

It was FDA-approved as Geref, later discontinued for commercial reasons, and FDA wrote into the federal record that the withdrawal was not about safety or effectiveness. We document what the human trials measured, what faded, and what was never shown, with every claim linked to its primary source.

  • 37Cited primary sources
  • 15Evidence-table entries, species-labeled
  • 102In-depth guides

Online care, from intake to delivery

Sermorelin care, made simple

Choose your plan, complete a private medical intake, and connect with a licensed provider. If prescribed, treatment ships discreetly to your door.

Sermorelin care catalog product image
Compounded injectable treatmentPrepared after approval
Catalog image. Dispensed product and packaging may vary by pharmacy.

Your care plan includes

Everything you need to get started

From$143.10per month
Licensed providerMedical reviewIf prescribedTreatment includedAt no added costDiscreet shippingWhen you need itOrder support
Choose your planChange or cancel future refills anytime
Due today$157.50then monthly

Encrypted checkout provider review required shipping included

  1. 01
    Choose your planSelect the supply and refill preference that works for you.
  2. 02
    Complete your intakeShare your health history in our private, secure flow.
  3. 03
    Provider reviewIf appropriate, your prescription is prepared and shipped.

Prescription treatment requires an online medical evaluation. A provider will determine whether treatment is medically appropriate; approval is not guaranteed.

Key facts

  • StatusCompounded, not FDA-approved
  • Parent half life6.8 minutes (GHRH 1-44 by HPLC) minsource
  • Clearance39.7 mL/kg per min (GHRH 1-29)source
  • OnsetGH release within 10 minutes of SC injectionsource
  • Durationsingle GH pulse lasting about 2 hourssource
  • Degradationcleaved by DPP-IV at the 2-3 bond to an inactive metabolitesource
  • ClassGHRH analog (GRF 1-29)Regulatory recordsource
  • Half-lifeabout 4 minutes minHuman trialsource
  • RouteSubcutaneous injection; bedtime in trialsHuman trialsource
  • Molecule29-amino-acid fragment of human GHRHReview or guidelinesource
  • First approvedDec 28, 1990 (Geref, diagnostic use)Regulatory recordsource
  • Discontinued2008, for commercial reasonsRegulatory recordsource
  • GH response onsetwithin 10 min, lasting about 2 hHuman RCTsource

Read the full Sermorelin monograph

Browse by topic

Everything on sermorelin, organized the way you research it.

study rows by species, from the evidence table

Low golden sunrise light streaming through a tall window onto a wide wooden floor, a sheer linen curtain glowing amber beside the window.
A brushed steel stovetop kettle and a small amber ceramic cup on a wooden counter in low morning light.

All guides

102 in-depth, individually cited guides.

Comparisons 43 guides

Sourcing 19 guides

Evidence 17 guides

Dosing 14 guides

Safety 9 guides

A wooden bedside table at dusk holding a glass carafe of water, a small glass, and a closed linen-bound book.
An open notebook with blank pages beside a stack of plain paper and a small amber ceramic cup on an oak desk in first light.

Follow the sermorelin evidence as it changes

One short email when something real happens: a new trial, a safety signal, or an FDA move on sermorelin or its class, each item cited to its primary source.

Free. No spam, unsubscribe anytime. Your address is used for this brief and nothing else.

Start provider review